Publication | Closed Access

Have Changing Palivizumab Administration Policies Led to More Respiratory Morbidity in Infants Born at 32-35 Weeks?

AsthmaRespiratory Morbidity32-35 WeeksNeonatologyPediatric EpidemiologyClinical EpidemiologyPediatricsPediatric Lung DiseaseMaternal HealthPreterm BirthNewborn MedicinePulmonary MedicinePublic HealthMedicineInfants Born